Search clinical trials for: FEX60/PE10

Total 142 results

Sanofi

Completed

A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis

Rhinitis Allergic

Japan
Prism Pharmaceuticals

Completed

A Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers

Healthy

Canada
Vitti Labs, LLC

Recruiting

A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI) (VL-POI-01)

Diminished Ovarian Reserve | Premature Ovarian Insufficiency

United States
National Taiwan University Hospital

Unknown

Acute Renal Failure in the Surgical Intense Care Units - NTUH-SICU-ARF (NSARF) Study

Sepsis | Acute Renal Failure | Postoperative

Taiwan
Neuromod Devices Ltd.

Completed

Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2 (TENT-A2)

Tinnitus

Ireland
Yuyu Pharma, Inc.

Active, not recruiting

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Dry Eye

United States
Vitti Labs, LLC

Recruiting

Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19

Pulmonary Fibrosis | COVID-19 Respiratory Infection

United States
Recombio SL
Eurofarma Laboratorios S.A.; Laboratorio Elea Phoenix S.A.; Innogene Kalbiotech... and other collaborators

Unknown

Immunotherapy With Racotumomab in Advanced Lung Cancer

NSCLC | Lung Cancer, Non-small Cell

Brazil, Indonesia, Argentina, Cuba, Philippines, Singapore, Thailand
Samsung Electronics

Terminated

Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting

Hepatic Disease

United States
Laboratorio Elea Phoenix S.A.

Completed

Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients

Advanced Non-small Cell Lung Cancer

Argentina
University of Michigan
National Institute on Aging (NIA)

Completed

Early Menopause Hormone Treatment and Cognition (R21)

Menopausal Syndrome

United States
Mayo Clinic
United States Department of Defense

Recruiting

3D Ultrasound Breast Imaging

Breast Tumor

United States
National Research Centre, Egypt
Cairo University

Completed

Cardiac Functions as a New Method for Evaluation of Fetal Anemia Pre and Post Intrauterine Fetal Blood Transfusion

Fetal Anemia as Antepartum Condition (Diagnosis) | Rh Incompatible Blood Transfusion Nos

Egypt
University of Aarhus

Completed

FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment

Giant Cell Arteritis

Denmark
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206)

Leukemia

Italy
Mikrobiomik Healthcare Company S.L.

Completed

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

Recurrent Clostridium Difficile Infection | Primary Clostridium Difficile Infection

Spain
Peter MacCallum Cancer Centre, Australia

Recruiting

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary (FAPI-CUP)

Cancer of Unknown Primary Site

Australia
Chonbuk National University Hospital

Unknown

Efficacy and Safety of Ethanol Extracts of Porphyra Tenera(PTE10) on Promotion of Immunity

Immunity

Korea, Republic of
Celltrion

Completed

To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Follicular Lymphoma

Korea, Republic of
Celltrion

Completed

PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab)

Rheumatoid Arthritis
Minneamrita Therapeutics LLC

Recruiting

Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Korea, Republic of
Fudan University
Inner Mongolia Yili Industrial Group Co., Ltd

Completed

Effect of a Probiotic Strain Lactobacillus Paracasei K56 on Metabolic Symptom - a Pilot Study

Obesity | Adiposity

China
Celltrion

Completed

Long-Term Efficacy and Safety of CT-P10 in Patients With RA

Rheumatoid Arthritis

Korea, Republic of
NIZO Food Research
FrieslandCampina

Completed

The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection (MIRRE)

Diarrhea

Netherlands
University of Washington
National Cancer Institute (NCI)

Terminated

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Indolent Adult Non-Hodgkin... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

EBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditions

United States
National Cancer Institute (NCI)

Completed

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia

United States
University of Washington
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Withdrawn

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Burkitt Lymphoma | Refractory Burkitt... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Grade 3a Follicular Lymphoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Sun Pharma Advanced Research Company Limited

Withdrawn

Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain

Acute Muscle Pain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Celltrion

Completed

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan (rituximab)

Lymphoma, Follicular
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
Imperial College London
Aristotle University Of Thessaloniki

Completed

Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control (HARMONY)

Hypertension

Greece, United Kingdom

Search clinical trials for: FEX60/PE10

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations